26100905
Evaluation of the Effectiveness of Surgical and Diagnostic Techniques in Patients With Steno-occlusive Diseases of the Cerebral Vessels
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 60 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 12.2027.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 12
Критерии включения
- Patients with ICA occlusion confirmed by CTA, MRA, and cerebral DSA.
- MRI ASL-confirmed hypoperfusion in the territory of the occluded ICA (decrease of ≥30% compared with the contralateral side)
- Language comprehension is preserved, with mild or no motor aphasia and no significant cognitive impairment.
- Patients aged from 18 to 80 years.
- Modified Rankin Scale (mRS) score 0-2.
- Informed consent is available from the patient or legal guardian.
- Accessible and reliable patients for follow-up
Критерии невключения
- Patients with large territorial infarction or marked cerebral atrophy on MRI.
- No evidence of regional hypoperfusion on ASL MRI relative to the contralateral hemisphere.
- Patients with a non-functioning STA-MCA bypass
- Patients aged under 18
- Patients with severe somatic conditions or mRS score > 3
- Patients with bilateral ICA occlusion, neurovascular disease (cerebral aneurysm or arteriovenous malformation)
- Patients with Contraindications to MRI, CTA, or DSA
- Cardiac conditions associated with a high risk of cerebral embolism, including prosthetic heart valves, infective endocarditis, intracardiac thrombus, sick sinus syndrome, cardiac myxoma, or cardiomyopathy with left ventricular ejection fraction <25% (atrial fibrillation, patent foramen ovale, and atrial septal aneurysm are not exclusion criteria).
- Severe systemic comorbidities, life expectancy <2 years, or a modified Rankin Scale (mRS) score >3.
- Pregnancy.
- Contraindications to MRI, CTA, DSA, iodinated contrast agents, or antiplatelet therapy required in the perioperative period.
- Participation in another interventional or experimental trial within the previous 12 months, including studies involving ionizing radiation
Источник: ClinicalTrials.gov, NCT07396025 · запись обновлена в реестре 9 февраля 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 1
- STA-MCA bypass patency — From enrollment to the further follow-up of 6, 12, and 24 months.
- Donor superficial temporal artery caliber — 6, 12, and 24 months after surgery
- Cerebral perfusion changes — 6, 12, and 24 months after surgery
Цель исследования
This study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. The evaluation involves an extensive angiographic analysis, including pre- and postoperative measurements of superficial temporal artery branch diameters, assessment of the Circle of Willis and collateral pathways, alongside cerebral perfusion metrics, cognitive status, and clinical outcomes. Major focus is directed towards evaluating the degree of intracranial revascularization following to extracranial-intracranial bypass by postoperative angiographic evaluations. This integrative strategy aims to refine surgical reasons, better predictions of functional and cognitive outcomes, minimize postoperative risks, and eventually improve the overall efficacy of treatment in this patient population.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07396025 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.